BCPEM
RIGL icon

Bain Capital Public Equity Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bain Capital Public Equity Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,096
Closed -$1.21M – 94
2017
Q4 		$1.21M Buy
+31,096
New +$1.18M 0.09% 65

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bain Capital Public Equity Management's RIGL Position: Q1 2018 in Review

Bain Capital Public Equity Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2018, closing a stake of 31,096 shares — an estimated $1.21M sold.

Bain Capital Public Equity Management first reported a position in RIGL in Q4 2017 and held it in 1 quarter. The position peaked at $1.21M in Q4 2017. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2018.

  • Bain Capital Public Equity Management reported no remaining Rigel Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 31,096 Rigel Pharmaceuticals shares in Q1 2018, an estimated $1.21M.
  • Bain Capital Public Equity Management first reported a position in Rigel Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Bain Capital Public Equity Management's Rigel Pharmaceuticals position peaked at $1.21M in Q4 2017.
  • 117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2018.

Based on Bain Capital Public Equity Management's 13F filing for Q1 2018, filed 15 May 2018.